Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
Session and Poster Details
Session Title: Breaking News: 2023 Clinical Trial Results in Pulmonary Medicine
Date and Time: Monday,
Session Location:
Presentation Title: Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study
Presenting Author:
Session Title: Poster Discussion Session. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE
Date and Time:
Session Location:
Poster Title: 401 - Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
Presenting Author:
The presentation and poster will also be made available in the “Posters and Publications” section of the
Following the positive results observed in the TORREY study and discussions with worldwide regulatory authorities, Gossamer plans to initiate a registrational Phase 3 clinical trial in patients with PAH in the third quarter of 2023.
About
Forward-Looking Statements
Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of initiation and enrollment of clinical trials for seralutinib, including the expected initiation of a Phase 3 clinical program for seralutinib. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; later developments with and / or feedback from global regulatory authorities or the FDA that may differ from prior feedback which may alter our planned Phase 3 clinical trial design and timing of initiation thereof; disruption to our operations from the COVID-19 pandemic, including clinical trial delays; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for seralutinib; regulatory developments in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005332/en/
For Investors and Media:
Gossamer Bio Investor Relations
ir@gossamerbio.com
Source: